# OnCo record nct06014528 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06014528/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06014528", "NCT06014528" ;
  schema:name "IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren"@en ;
  schema:description "A phase 2 trial of IN10018, Pegylated liposomal doxorubicin in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06014528/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06014528> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-09-06" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/in10018/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/> ;
  onco:companies <https://onco.cc/companies/inxmed/> .